Recurrent Epithelial Ovarian
1 clinical trials · Condition
◉ Watch Recurrent Epithelial Ovarian
| Record | Firm | Date |
|---|---|---|
| Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies (NCT01974765) | Memorial Sloan Kettering Cancer Center | 2013-11-05 |
Track Recurrent Epithelial Ovarian automatically
Every clearance here is in the API, with alerts when new ones post.